Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1

Status

Completed 19Recruiting 12Terminated 5Active not recruiting 5Withdrawn 3Unknown 3Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Neoadjuvant Therapy 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Unknown × abiraterone × Clear all
NCT06134271 2023-11-18

RASTOM

First Hospital of China Medical University

Phase 2 Unknown
160 enrolled
Genitourinary

Prostatic Neoplasms

NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
30 enrolled

Neoadjuvant Therapy

NCT02254785 2017-12-06

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

British Columbia Cancer Agency

Phase 2 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡